GleamWall
中文EN

CMPX Compass Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—

Leverage & solvency

Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$850,000
R&D expense$55.97M$42.34M
SG&A expense$16.87M$15.13M
Operating income-$72.84M-$56.62M
Income tax$0$0
Net income-$66.49M-$49.38M
EBITDA-$72.56M-$56.04M
EPS (basic)-0.42-0.36
EPS (diluted)——
Weighted avg. shares (diluted)—137.40M
Balance sheet
Cash & equivalents$30.64M$43.48M
Short-term investments$178.26M$83.24M
Current assets$209.82M$132.75M
PP&E, net$102,000$353,000
Total assets$219.59M$140.40M
Current liabilities$13.97M$8.87M
Total liabilities$22.80M$15.17M
Shareholders' equity$196.79M$125.23M
Shares outstanding178.32M137.82M
Cash flow statement
Operating cash flow-$49.14M-$44.85M
Capital expenditure$25,000$44,000
Free cash flow-$49.17M-$44.90M
Investing cash flow-$93.31M$46.77M
Financing cash flow$129.61M$17.34M
Depreciation & amortization$276,000$589,000
Stock-based compensation$8.37M$8.56M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.